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Abstract
Aim: The aim of this study was to evaluate changes in proteinuria in dogs naturally infected with visceral leishmaniasis, 
following treatment with miltefosine (MLF) and allopurinol.
Materials and Methods: Medical records of 40 dogs with leishmaniasis, treated with 2 mg/kg MLF every 24 h PO and 
10 mg/kg allopurinol every 12 h for 28 days were reviewed. 20 dogs were included in the study, and clinical staging 
was performed following guidelines of the Canine leishmaniasis (CanL) Working Group, and dogs were categorized for 
proteinuria according to the International Renal Interest Society (IRIS) staging system. Clinical score, indirect fluorescent 
antibody test titer, serum total protein, gamma globulin (IgG), serum creatinine and urea concentration, and urine protein 
creatinine ratio (UP/C) were recorded at the time of diagnosis before the start of therapy (D0) and at the end of 28 days of 
therapy (D28).
Results: Following the CanL Working Group staging, all 20 dogs were classified as the clinical Stage C (Clinical disease) 
before and after the cycle of treatment. Before the cycle of therapy, dogs were categorized according to the IRIS staging 
system, as: 9/20 non-proteinuric (NP), 7/20 borderline proteinuric (BP), and 4/20 proteinuric (P). After treatment, 12/20 
dogs were NP, 7/20 were BP, and 1/20 was P. There was a significant change in UP/C values before and after one cycle of 
treatment with MLF. In detail, after 28 days of therapy, 2 of 9 NP dogs became BP, 3 of the 7 BP dogs became NP, and 2 of 
the 4 P dogs became NP.
Conclusion: This study showed a significant decrease in UP/C values occurred after one cycle of treatment with MLF and 
allopurinol in dogs naturally affected with CanL. This suggests that MLF does not increase proteinuria, and the use of MLF 
could be considered for the management of dogs with leishmaniasis, particularly in those with impaired renal function at 
the time of diagnosis.
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Introduction
Canine leishmaniasis (CanL) is a life-threat-
ening zoonotic disease widely spread throughout 
the Mediterranean basin and caused by a flagellate 
protozoan, Leishmania infantum [1]. The main clin-
ical findings of CanL are weight loss, muscle atro-
phy, lymphadenomegaly, dermatological lesions, 
non-regenerative anemia, serum hyperproteinemia, 
polyclonal hyperglobulinemia, decreased albumin/
globulin ratio, renal azotemia, and persistent renal 
proteinuria [2]. In dogs with clinical signs of CanL, 
there is an immune system shift toward a humoral 
(Th2) response. The activation of B-cells pro-
duces high levels of immunoglobulin and produc-
tion of immune-complexes composed of IgG, IgM, 
and/or IgA [3,4]. Immune-mediated mechanisms 
play a pivotal role in the development of renal 
pathology [5,6].
In dogs with CanL, it is important to monitor 
proteinuria using the urinary protein creatinine ratio 
(UP/C), as proteinuria is one of the first signs of renal 
impairment [2,7]. Moreover, it is essential that drugs 
used for the treatment of CanL have a low impact on 
the kidneys, particularly in dogs with impaired renal 
function at the time of diagnosis [8].
The standard protocol for treatment of CanL 
has been combination therapy with meglumine anti-
moniate and allopurinol [9,10]. Miltefosine (MLF) 
(in combination with allopurinol) is the most com-
monly used alternative treatment to meglumine anti-
moniate and the only oral drug for the treatment of 
CanL [11,12]. Multiple in vivo and in vitro trials have 
demonstrated its leishmania killing activity [13], 
which is effected through disruption of both signaling 
pathways and cell membrane synthesis, inducing an 
apoptosis-like cell death. A recent study [8] reported 
that MLF has limited impact on kidney function in 
healthy dogs, and no glomerular or tubular lesions 
were found on kidney biopsies in healthy dogs exper-
imentally treated with MLF. The suggestion is that 
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proteinuria does not increase in dogs treated with 
MLF. The importance of minimizing renal impair-
ment in dogs with CanL means that the choice of a 
safe pharmacological treatment is crucial.
The aim of this study was to evaluate changes in 
proteinuria before and after treatment with MLF and 
allopurinol in dogs naturally infected with leishmania-
sis. In addition, the variations between serum levels of 
total globulin, total protein (TP), urea, creatinine, and 
antibodies, before and after treatment, were evaluated.
Materials and Methods
Ethical approval
This retrospective study was performed at the 
Department of Veterinary Sciences for Health, Animal 
Production and Food Safety (VESPA) of the University 
of Milan, and it did not include experimental animals, 
and it was performed on client-owned dogs referred 
to our institution for therapeutic purpose. All own-
ers gave informed consent for treatments, measure-
ments, and for data recording. The study was carried 
out in accordance with Italian law (DL 14th March 
2014 n.26) and Europe Union legislation covering 
the use of animal for the scientific purpose (“Animal 
Scientific Procedures Act” 63/2010/EU) and with the 
Institutional Ethical Guidelines.
Inclusion criteria and clinical procedures
A retrospective review was carried out of the 
medical records of 40 dogs with confirmed leishman-
iasis presented at the Internal Medicine Service of 
the Department of Health, Animal Science and Food 
Safety, University of Milan, Italy, between 2008 and 
2014 that had received a leishmanicidal therapy with 
2 mg/kg q 24 h PO of MLF in combination with allo-
purinol at 10 mg/kg q 12 h for 28 days PO.
Data collection
Dogs were eligible for inclusion in the study 
if they fulfilled the following criteria: Physical 
examination at the first consultation and the end of 
the cycle of MLF treatment, with severity of signs 
referable to CanL scored on the basis of clinical 
score according to the signs reported in a previous 
study [14]; assigning a value from 0 to 3 to each 
parameter, depending on the severity of each sign, 
with a maximum achievable score of 86/86 [15]; a 
diagnosis of leishmaniasis established by clinicopath-
ologic abnormalities, positive serology for L. infan-
tum using immunofluorescence antibody (IFA) test 
and cytologic identification of leishmania amastig-
otes, or detection of parasite DNA using polymerase 
chain reaction in either lymph node or bone marrow 
aspirates according to diagnostic criteria previously 
described [2]; hematological and serum biochemical 
blood examination, IFA test for CanL and complete 
urinalysis, on samples collected by cystocentesis, 
including UP/C, at the time of the diagnosis and at 
the end of the cycle of MLF treatment; residence in 
a CanL non-endemic area of Northern Italy (to avoid 
any possible reinfection).
All dogs with other neoplastic, degenerative, 
inflammatory, endocrine, immunologic, and genetic 
diseases potentially associated with proteinuria were 
excluded. Dogs were also excluded if they had con-
comitant infectious diseases (e.g. babesiosis, ehrlichi-
osis, and dirofilariasis) diagnosed by parasitological 
or serological examinations. Any dogs receiving addi-
tional medical treatment, including nephrotoxic drugs 
and those that might change proteinuria, e.g. steroids 
and angiotensin-converting enzyme inhibitors, were 
also excluded.
The following information was extracted from 
the medical records of each dog: Signalment (age, sex, 
breed, and provenance/travel history), clinical score 
with clinicopathological signs of CanL, indirect flu-
orescent antibody test (IFAT) titer, serum TP, gamma 
globulin (IgG), serum creatinine and urea concentra-
tions, and UP/C. Data were recorded at the time of the 
diagnosis before the start of therapy (D0) and at the 
end of the 28 days treatment period (D28).
Dogs were classified on the basis of stage of dis-
ease following the clinical staging of the CanL Working 
Group [16]. Dogs were considered to be Stage A 
(exposed) when they had no clinical signs, tested neg-
ative for parasites, and had a low antibody titer; in 
Stage B (infected), when they had no clinical signs, 
positive identification of parasite, and had a low anti-
body titer; in Stage C (clinical disease), when they had 
clinical signs and/or clinicopathological abnormalities 
associated with leishmaniasis, positive identification 
of parasite and/or antibody titer >4 times the reference 
value; in Stage D (severe clinical disease), when they 
had all signs of Stage C and severe concomitant signs 
such as proteinuria, severe kidney disease or severe 
ophthalmic or joint disease. Dogs were also classified 
on the basis of UP/C value according to the International 
Renal Interest Society (IRIS) guidelines (http://www.
iris-kidney.com, 2016-01-20). Dogs were considered: 
Non-proteinuric (NP) when UP/C was <0.2; borderline 
proteinuric (BP) when UP/C was 0.2 to 0.5, and pro-
teinuric (P) when UP/C was more than 0.5.
Statistical analysis
Data statistical analyses were performed using 
commercial statistical software (MedCalc, v.12.3.0). 
The distribution of data was assessed using descrip-
tive statistics Kolmogorov–Smirnov test. Parameters 
before and after therapy were compared using a paired 
t-test when the data were normally distributed, or the 
non-parametric Wilcoxon matched paired-test when 
the data were not normally distributed. The level of 
significance was set at p<0.05.
Results
A total of 20/40 dogs met the criteria for inclu-
sion in the study. Ages of these 20 dogs ranged from 
1 to 14 years. 14 were intact males and 6 were female 
(4 neutered), 14 were X-breeds and 6 were purebreds.
Following the staging of CanL as previous 
described [16], before and after the cycle of treatment, 
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all 20 dogs were classified as clinical Stage C (clini-
cally diseased). Mean, median, and confidence inter-
val 95% and p-value of the clinical score, IFAT titer, 
TP, gamma globulin, creatinine, urea, UP/C before 
and after therapy for the 20 dogs treated are reported 
in Table-1. The value of UP/C in each subject before 
and after the treatment is reported in Table-2.
According to IRIS staging system before the 
cycle of MLF and allopurinol, 9/20 were NP, 7/20 were 
BP, and 4/20 were P. After treatment, 12/20 dogs were 
NP, 7/20 were BP, and 1/20 was P. In particular, 2 of 9 
NP dogs became BP, 3 of 7 dogs with BP became NP, 
and the other 3 remained BP, but P decreased; 2 of 4 P 
dogs became NP.
Except the value of UP/C, there were no signif-
icant differences between any parameters before and 
after the cycle of therapy with miltefosine and allopu-
rinol. All dogs demonstrated clinical response to ther-
apy, with significant improvement of the clinical score 
and a reduction of UP/C mean value.
Discussion
The glomerulonephropathy that character-
izes CanL is the result of a glomerular deposition 
of circulating immune complexes from persistent 
antigenemia [17]. The consequent activation of the 
complement system causes injury to the glomerular 
capillaries and mesangium [17]. Immune complex 
deposition in glomeruli causes glomerulonephritis and 
proteinuria [18]. Even though some studies report new 
markers of renal damage in dogs with CanL, such as 
ferritin and cystatin C concentrations [19] and urinary 
gamma-glutamyl transferase value [20], proteinuria is 
still considered the earliest sign of kidney injury in 
CanL [2]. There is strong evidence that proteinuria 
is a risk factor for the development and progression 
of renal failure which is the most severe complica-
tion of CanL and carries a poor prognosis [17,18,21]. 
Furthermore, a recent study highlights the correlation 
between elevated blood pressure and increased UP/C 
in dogs with CanL [22]. So, it is important that any 
drug used for the treatment of CanL does not alter 
renal function and does not increase the magnitude of 
proteinuria. Some studies in dogs have reported the 
short-term efficacy of MLF therapy in association 
with allopurinol and reported that this combination is 
a safe, convenient, and effective alternative treatment 
option for CanL, producing only mild (and self-limit-
ing) side effects [23-26]. A controlled study [20] has 
evaluated the effectiveness and safety of MLF and 
allopurinol therapy in CanL reporting that renal and 
hepatic parameters were not affected by the therapy.
Bianciardi et al. [8] evaluated the pharmacolog-
ical and toxicological effects of meglumine antimo-
niate and MLF in healthy dogs experimentally treated 
and submitted to renal biopsy after 27 days of treat-
ment, showing that in the MLF-treated group there 
were no ultrastructural lesions, while tubular dam-
age was found in the meglumine antimoniate treated 
group.
The results of our study are in accordance with 
the previous report of Bianciardi et al. [8] since we 
found a significant reduction of proteinuria after 
28 days of therapy with miltefosine and allopurinol 
in dogs naturally affected with CanL. In fact, after 
28 days of therapy, 2 of 4 P dogs became NP and 3 of 7 
Table-1: Mean, median, 95% CI, interquartile interval and P value of clinical score, IFAT titer, TP (g/dl), IgG (%), 
creatinine and urea (mg/dl), and UP/C in 20 dogs before and after 28 days of therapy.
Parameter D0 D28 p value
Clinical score
NV: 0
Mean (95% CI)
5.1
(3.1-7.09)
2.6
(1.52-3.77)
p=0.0046
IFAT titer
NV: Titer<1:80
(min-max)
160-1280
(320-640)
80-1280
(240-640)
p=0.2661
TP
NV: 6-8 g/dl
Mean (95% CI)
8
(7.55-8.45)
7.6
(7.24-7.96)
p=0.0730
IgG
NV: 5.3-9.9%
Mean (95% CI)
21.36
(16.89-25.83)
19.06
(14.75-23.36)
p=0.1009
Creatinine
NV<1.2 mg/dl (Median I-III interquartile 
interval)
0.91
(0.8-1.05)
0.91
(0.7-1.1)
p=0.8077
Urea
NV: 15-45 mg/dl
(Median I-III interquartile interval)
40.75
(29-45.5)
38.55
(29.5-44)
p=0.4171
UP/C
NP: <0.2
BP: 0.2-0.5
P: >0.5
(Median I-III interquartile interval)
0.35
(0.1-0.7)
0.26
(0.1-0.4)
p=0.016
NV: Normal value, NP: Non-proteinuric, BP: Borderline proteinuric, P: Proteinuric, CI: Confidence interval 95%, TP: Total 
protein, IFAT: Indirect fluorescent antibody test, UP/C: Urine protein creatinine, IgG: Gamma globulin
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BP dogs became NP. All dogs receiving any treatment 
to reduce proteinuria, other than allopurinol, were 
excluded from the study to isolate the effects of MLF.
All dogs in this study demonstrated clinical 
response to therapy, with significant improvement of 
the clinical score; this is in agreement with results of 
previous studies [23-26]. There was no statistically 
significant difference between D0 and D28 for any 
of the measured parameters except the value of UP/C. 
Moreover, there was a reduction in the mean percent-
age of IgG in the mean concentration of TP and the 
mean value of IFAT titer. Despite the improvement in 
the average value of these parameters, they remained 
above normal limits. This finding does not indicate a 
lack of efficacy of treatment because the therapeutic 
effect of MLF persists after the 28 days of therapy. 
This long-lasting activity of MLF may be attributed 
to its long elimination half-life in canines, leading to 
a high level of drug accumulation with persistence of 
therapeutic effects after the treatment period [25]. In 
addition, CanL affects multiple organs and systems, 
resulting in polymorphic perturbations in hematologic 
and biochemical parameters that might require differ-
ent times to resolve.
We would like to emphasize that recent stud-
ies [16,26] report that the effects of meglumine anti-
moniate in combination with allopurinol are better than 
MLF with allopurinol for treatment of leishmaniasis 
in dogs because there was a decrease in the incidence 
of disease recurrence in dogs treated with meglumine 
antimoniate plus allopurinol. The clinician must care-
fully assess the relationship between safety and effi-
cacy when selecting therapy. The results of this study 
provide a clinically relevant finding that could aid the 
clinical management of proteinuric dogs with leish-
maniasis and may help to establish a treatment regime 
that reduces the progression of renal disease. Because 
of the small number of dogs included in this study and 
the short period of follow–up, results need to be con-
firmed in a larger study including a larger number of 
dogs followed over a longer period before any firm 
conclusions can be made.
Conclusion
In conclusion, significant decreases in UP/C 
value occurred after one cycle of treatment with MLF 
and allopurinol in dogs affected with CanL. This sug-
gests that MLF does not increase proteinuria and treat-
ment with MLF could be considered in the manage-
ment of dogs with leishmaniasis with impaired renal 
function at the time of diagnosis.
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